In RCC, it appears that VHL is the sole contributor to disruption of VHL elongin BC complex, whereas, in PCC, VHL elongin BC complex loss of function may occur frequently through CNL of VHL, RBX1, and CUL5 and through mutation of VHL. Here, CUL5 is linked to renal cell carcinoma.